10 Takeover Targets to Watch This Fall
Pace of Biopharma M&A Slows from First Half Stampede of Deals
Scaling Up Cell Therapy Manufacturing
Moving Forward with an Early-on Strategy
Bioprocessing Companies Push Limits of Upstream Technologies
Goal Is to Maximize Efficiency in Bioprocess Operations
In the mAb Race, Don’t Stumble at Characterization
Researchers Adapt Existing Techniques to Deal with Challenging New Monoclonal Antibodies
For full access to this article login to GEN Select now.
Phenotypic Drug Discovery in 3D
Testing Drug Efficacy by Rapid Size Profiling Over Time with Tumor Microtissues
- It is commonly accepted that tumor sensitivity or resistance to chemotherapeutic agents is not only genetically determined, but also driven by the tumor microenvironment. Metabolic gradients and the extracellular matrix can influence nutrient availability to various segments of a solid tumor, and also limit the ability to administer an ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.